Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression.
Adjunctive use of methylphenidate, a central stimulant, has been considered as a potential therapeutic choice for patients with refractory unipolar depression, geriatric depression, bipolar depression, and depression secondary to a medical illness. We present a case of psychotic unipolar depression in which the patient responded significantly to the adjunctive use of methylphenidate. A 45-year-old woman had melancholic depressive symptoms and mood incongruent psychotic features during her second episode of unipolar depression. She attempted suicide by hanging herself and was forcibly hospitalized. She was initially treated with venlafaxine (262.5 mg/d), olanzapine (20 mg/d), and benzodiazepines. However, she responded unsatisfactorily to the combination treatment. Because her family refused electroconvulsive treatment, we added methylphenidate to her medications for adjunctive use. The dose of methylphenidate was started at a dose of 5 mg/d. It was not until the patient received 30 mg/d of methylphenidate that her persistent psychosis and severe depression were substantially improved. She tolerated her medications well and did not report any side effects. She was discharged in a stable condition 2 weeks after the adjunctive use of methylphenidate. The patient's methylphenidate was gradually tapered and finally discontinued. To date, she remains well and is regularly followed up at our outpatient clinic. Our case suggests that adjunctive use of methylphenidate can be a therapeutic option in treating some patients with psychotic unipolar depression who do not adequately respond to the combination treatment of an antidepressant and an atypical antipsychotic. Further controlled studies are warranted to verify this.
Huang
Chang-Chih
CC
Department of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan.
Shiah
I-Shin
IS
Chen
Hsing-Kang
HK
Mao
Wei-Chung
WC
Yeh
Yi-Wei
YW
D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use*; D008875:Middle Aged; D000077152:Olanzapine; D013406:Suicide, Attempted; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
D014151:Anti-Anxiety Agents; D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D003511:Cyclohexanols; D001569:Benzodiazepines; D008774:Methylphenidate; D000069470:Venlafaxine Hydrochloride; D000077152:Olanzapine